Diamyd Medical AB ser. B (DMYD_B.ST) revealed Loss for full year of -SEK169.78 million
The company's bottom line came in at -SEK169.78 million, or -SEK1.5 per share. This compares with -SEK151.85 million, or -SEK1.6 per share, last year.
Revenue came in at SEK0.130 million, equal to the mark posted in the same period last year.
Diamyd Medical AB ser. B earnings at a glance (GAAP) :
-Earnings: -SEK169.78 Mln. vs. -SEK151.85 Mln. last year.-EPS: -SEK1.5 vs. -SEK1.6 last year.-Revenue: SEK0.130 Mln vs. SEK0.130 Mln last year.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.